Belite Bio, Inc
BLTE
$90.37
$2.663.03%
NASDAQ
| 12/31/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2021 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 100.81% | 383.17% | 34.97% | 40.00% | 41.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 64.73% | 156.09% | 21.03% | 3.48% | 37.64% |
| Operating Income | -64.73% | -156.09% | -21.03% | -3.48% | -37.64% |
| Income Before Tax | -44.47% | -139.68% | -14.17% | -3.05% | -35.81% |
| Income Tax Expenses | 100.00% | -- | 0.00% | -- | -- |
| Earnings from Continuing Operations | -44.49% | -139.58% | -14.16% | -3.04% | -35.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.49% | -139.58% | -14.16% | -3.04% | -35.81% |
| EBIT | -64.73% | -156.09% | -21.03% | -3.48% | -37.64% |
| EBITDA | -64.95% | -156.18% | -20.81% | -3.21% | -37.57% |
| EPS Basic | -30.01% | -89.55% | 19.42% | 9.23% | -25.51% |
| Normalized Basic EPS | -30.07% | -- | -- | 9.24% | -25.51% |
| EPS Diluted | -30.01% | -89.55% | 19.42% | 9.23% | -25.51% |
| Normalized Diluted EPS | -30.07% | -- | -- | 9.24% | -25.51% |
| Average Basic Shares Outstanding | 11.10% | 26.37% | 41.66% | 13.52% | 8.22% |
| Average Diluted Shares Outstanding | 11.10% | 26.37% | 41.66% | 13.52% | 8.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |